Azacitidine
Acute Myeloblastic Leukemia Without Maturation
Explore 5 assets in Acute Myeloblastic Leukemia Without Maturation →Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
University of Chicago
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01839240CT.gov Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01260714CT.gov Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT01168219CT.gov Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00895934CT.gov Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML | — | Completed | — | — | — |
NCT00658814CT.gov Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloblastic Leukemia Without Maturation
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Azacitidine (this asset) | University of Chicago | P2 | BB · 69 |
| Etoposide | Stanford University | P3 | BBB |
| Cytarabine | Northwestern University | P3 | BBB |
| Daunomycin | National Cancer Institute (NCI) | P3 | BBB |
| Cyclophosphamide | Fred Hutchinson Cancer Center | P3 | BBB |
| Idarubicin | Bruno C. Medeiros | P3 | BBB |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P3 | BBB |
| Mitoxantrone | Stanford University | P2 | BBB |
| Nivestim | Rutgers, The State University of New Jersey | P3 | BB |
+42 more in the Acute Myeloblastic Leukemia Without Maturation cohort
Other indications for Azacitidine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BBB · 73 |
| Acute Erythroid Leukemia | — | P2 | BB · 71 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Azacitidine in Acute Myeloblastic Leukemia Without Maturation. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/azacitidine-acute-myeloblastic-leukemia-without-maturation
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →